Drug Profile
PAS 004
Alternative Names: CIP-1374; CIP-137401; PAS-004Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Cheminpharma
- Developer Cheminpharma; Pasithea Therapeutics
- Class Antineoplastics; Macrocyclic compounds; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Neurofibromatosis 1; Noonan syndrome
Most Recent Events
- 15 Feb 2024 Pasithea Therapeutics plans a phase II trial for Neurofibromatosis 1 (In Children, In adults) at unknown location (PO)
- 13 Feb 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO)
- 08 Jan 2024 Pasithea Therapeutics files for patent protection for crystalline form of PAS 004